Sekisui XenoTech, LLC

1101 West Cambridge Circle Drive
Kansas City
Kansas
66103
United States

Tel: 877-588-7530; 913-438-7450
Fax: 855-698-4631; 913-227-7100

About Sekisui XenoTech, LLC

Sekisui XenoTech, LLC is a global Contract Research Organization with unparalleled experience and proven expertise from discovery through clinical support, providing cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADMET and pharmacology, in vivo ADMET and QWBA, metabolite ID and production, bioanalytical services and consulting. Sekisui XenoTech's product selection includes a wide-range of high quality standard reagents, from subcellular fractions and hepatocytes to recombinant enzymes, substrates and metabolites. The company also regularly prepares and delivers custom-designed products and services in response to client requests.
YEAR FOUNDED:
1994
LEADERSHIP:
CEO: Yasuhisa Adachi
Chief Scientific Officer: David Buckley

12 articles about Sekisui XenoTech, LLC

New Head of KC-based Drug Development CRO poised for further growth and expansion

1/28/2020

Kansas City, KS- SEKISUI XenoTech announces the promotion of Dr. Darren Warren, PhD to President and Chief Executive Officer.
SEKISUI XenoTech Announces Expanded Consulting Opportunities Available to Clients

9/5/2019

KS- SEKISUI XenoTech now provides the opportunity for clients to work with top-tier consultants to analyze critical components of absorption, distribution, metabolism, and excretion of their drug candidate to optimize the data package for regulatory submission.
SEKISUI XenoTech Announces Enhanced Synergy in ADME Testing Services

7/2/2019

SEKISUI XenoTech is collaborating with the Drug Development Solutions Center to offer a full suite of nonclinical testing servicesspecializing in the evaluation of Absorption, Distribution, Metabolism, and Excretion (ADME) in potential new drugs.
SEKISUI XenoTech Achieves Record Revenue and Employment Numbers

5/21/2019

SEKISUI XenoTech will celebrate its 25th anniversary this November, coming into the year with record-breaking achievements.
Celebrating 10 Years of Sekisui XenoTech

9/19/2018

American Innovation Meets Japanese Vision with a Global Outlook
Sekisui XenoTech Adds Rodent, Monkey Hepatocytes to Patented CryostaX® Product Line

9/12/2018

Company Anticipates the End of Traditionally Cryopreserved Hepatocytes
Sekisui XenoTech Hiring and Growing to Meet Customer Demand

1/3/2018

The company hired a record number of new staff over the past year in order to meet current demand for its products and services, which are utilized to optimize the discovery, development, and approval of new drugs and other compounds.
Sekisui XenoTech Establishes Method For High Aldehyde Oxidase And Xanthine Oxidase Activity In Pooled Human Liver Test Systems

8/14/2017
Sekisui XenoTech Awarded Cryopreservation Patent, Achieves Numerous Hepatocyte Enhancements URL

5/10/2017
Sekisui XenoTech Adds New Dermal Subcellular Fraction Test Systems

2/2/2017
Sekisui XenoTech Introduces Lysosomal Test Systems For Biopharmaceutical Development

10/6/2016
Sekisui XenoTech Expands Hepatotoxicity Testing Services

8/3/2016